Manage Your
Psoriasis Today
Psoriasis Today
The University of California, San Francisco is conducting a study that an FDA-approved biologic medication to treat people suffering from plaque or guttate soriasis.
San Francisco, CA
Compensation Provided
Up to 96 Weeks Treatment
Moderate-to-Severe
Plaque or Guttate Psoriasis
Plaque or Guttate Psoriasis
18 Years and Older
Fast Facts
About our research study:
Psoriasis is a largely treatable but misunderstood condition. Over 7.5 million people in the USA struggle with the condition today and the condition can lead to additional comorbidities.
Researchers are investigating an FDA-approved biologic medication, Tremfya, and its ability to lead to remission and quality of life improvements in patients with plaque or guttate psoriasis.
By joining this study, you will get access to free biologic medication that could lead to improvements in your psoriasis and daily life. Help us learn more about this treatment and the effects on your skin cells.
Researchers are investigating an FDA-approved biologic medication, Tremfya, and its ability to lead to remission and quality of life improvements in patients with plaque or guttate psoriasis.
By joining this study, you will get access to free biologic medication that could lead to improvements in your psoriasis and daily life. Help us learn more about this treatment and the effects on your skin cells.
Additional Information
This study is looking at how treatment with an FDA-approved biologic medication, Tremfya, can lead to remission and quality of life improvements in patients with plaque or guttate psoriasis.
You may be eligible if you meet the following criteria.
Criteria:
Criteria:
- Are over 18 years of age.
- Diagnosis of guttate or plaque psoriasis
- Affected by condition in more than 5% of your body
- Do not have a history of active, chronic, or recurrent infectious disease, including HIV, hepatitis B, or hepatitis C
- Do not have known allergies, hypersensitivity, or intolerance to guselkumab (Tremfya)
- If female: are not pregnant, nursing, or planning a pregnancy while enrolled in the study (96 weeks)
In the study, you will be treated with guselkumab, also known as Tremfya, for up to 96 weeks. Study visits will occur every 1-2 months. During the study visits, questionnaires, photographs, throat cultures, and skin samples may be taken.
Prior to the screening visit, we would go through the consent form with you, which fully describes the study along with its benefits and risks. We anticipate the consent and screening visit to take around an hour and the research visits to take about 1-2 hours.
Prior to the screening visit, we would go through the consent form with you, which fully describes the study along with its benefits and risks. We anticipate the consent and screening visit to take around an hour and the research visits to take about 1-2 hours.
Compensation is provided for participation in this study.
There is no cost for the study medicine or study tests.